These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 20008189)
1. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Rodeghiero F; Castaman G; Tosetto A Hematology Am Soc Hematol Educ Program; 2009; ():113-23. PubMed ID: 20008189 [TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A; Berneman Z; Schroyens W; Michiels JJ Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [TBL] [Abstract][Full Text] [Related]
3. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management. Michiels JJ; van Vliet HH Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362 [TBL] [Abstract][Full Text] [Related]
4. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings. Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363 [TBL] [Abstract][Full Text] [Related]
5. Von Willebrand Disease and Pregnancy: A Review of Evidence and Expert Opinion. Reynen E; James P Semin Thromb Hemost; 2016 Oct; 42(7):717-723. PubMed ID: 27648611 [TBL] [Abstract][Full Text] [Related]
6. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3. Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574 [TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of von Willebrand disease in Australia. Favaloro EJ; Bonar R; Favaloro J; Koutts J Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198 [TBL] [Abstract][Full Text] [Related]
8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [TBL] [Abstract][Full Text] [Related]
9. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene. Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361 [TBL] [Abstract][Full Text] [Related]
10. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect. Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565 [TBL] [Abstract][Full Text] [Related]
11. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1. Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353 [TBL] [Abstract][Full Text] [Related]
12. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279 [TBL] [Abstract][Full Text] [Related]
13. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1. Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358 [TBL] [Abstract][Full Text] [Related]
14. Management of inherited von Willebrand disease in 2007. Federici AB; Mannucci PM Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477 [TBL] [Abstract][Full Text] [Related]
16. Von Willebrand's disease: case report and review of literature. Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis of inherited von Willebrand disease: a clinical perspective. Federici AB Semin Thromb Hemost; 2006 Sep; 32(6):555-65. PubMed ID: 16977566 [TBL] [Abstract][Full Text] [Related]
18. How I treat patients with von Willebrand disease. Mannucci PM Blood; 2001 Apr; 97(7):1915-9. PubMed ID: 11264151 [TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience. Akin M; Kavakli K Semin Thromb Hemost; 2011 Jul; 37(5):581-6. PubMed ID: 22102203 [TBL] [Abstract][Full Text] [Related]
20. Advances in the diagnosis and management of von Willebrand disease. Franchini M Hematology; 2006 Aug; 11(4):219-25. PubMed ID: 17178659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]